Tranexamic Acid: A Paradigm Shift in Total Joint Care

Kenoma Anighoro, MD, MBA; Alan Reznik, MD, MBA, FAAOS

Years ago, total joint arthroplasty (TJA) postoperative protocols consisted of two-week hospital stays and multiweek stays in nursing care facilities.

Reader Comments on Delaying ACLR and Arthrofibrosis

K. Donald Shelbourne, MD

Editor’s note: The following letter is in response to the August 2022 AAOS Now article titled “Delaying ACL Reconstruction by Seven Weeks or More Is Associated with Lower Risk of Arthrofibrosis” by Ariel DeMaio.

AAOS to Host Second Annual Biologics Symposium

This year, AAOS will host its second annual biologics symposium, titled “The Next Generation of Biologics: Use of Real-world Evidence,” in Washington, D.C. It is designed to convene experts in science and medicine, industry, as well as regulatory agencies to examine current real-world evidence as it pertains to musculoskeletal medicine.

ICL Elucidates Regulatory Guidelines on Orthobiologics

Patrick Daly

Scott Bruder, MD, PhD, founder and CEO of Bruder Consulting & Venture Group, was the first presenter in the Instructional Course Lecture (ICL) titled “Orthobiologics Use and Marketing: U.S. Food and Drug Administration, Federal Trade Commission, and Ethical Compliance,” which discussed the complex regulations surrounding the use of orthobiologics.